Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MDM2 and MDMX are key oncogenic proteins driving cancer proliferation.
• Targeting MDM2/MDMX is a promising therapeutic strategy for various cancers.
• Current therapies often rely on TP53 status, limiting their application.

Purpose of the Study:

• To evaluate the anti-proliferative effects of a novel MDM2 dimerization inhibitor, DRx-098D.
• To explore the therapeutic potential of targeting MDM2 homo- and heterodimerization.
• To assess DRx-098D's efficacy across different TP53 mutational statuses.

Main Methods:

• Utilized a novel cell-penetrating peptide, DRx-098D, designed to disrupt MDM2 dimerization.
• Tested DRx-098D against a panel of human cancer cell lines with wild-type, mutant, or null TP53.
• Compared DRx-098D's mechanism and efficacy against idasanutlin, an MDM2-p53 inhibitor.

Main Results:

• DRx-098D demonstrated significant anti-proliferative activity by blocking MDM2 dimerization.
• The peptide showed superior growth inhibition in TP53-null HCT116 cells compared to idasanutlin.
• DRx-098D exhibits a distinct anti-cancer mechanism compared to MDM2-p53 inhibitors.

Conclusions:

• DRx-098D represents a first-in-class therapeutic agent targeting MDM2 homo- and heterodimerization.
• This approach offers a novel strategy for treating cancers dependent on MDM2/MDMX, irrespective of TP53 mutational status.
• Preliminary data suggest therapeutic utility in TP53 wild-type and mutant cancers.